Journals / Journal of Neurological Sciences (Turkish) / 2017 / Cilt: 34 - Sayı: 1

Dikloronitrofenolün Amiloid Beta Toksisitesi ve Steroid Düzeylerine Etkisi

The Effect of Dichloronitrophenol on Amyloid Beta Toxicity and Steroid Levels

Pages
16–31
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to our literature knowledge, this is the first study to show the beneficial effects of DCNP on AB toxicity

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In Alzheimer's disease (AD), which is the most common cause of dementia, the accumulation of amyloid beta (AB) peptides has a causal role in the neurodegeneration process.
📊
Key Findings & Data:Nitrophenols can inhibit the aggregation of AB peptides at relatively low concentrations. 2,4dichloro-6-nitrophenol (DCNP) is a small water-soluble derivative of nitrophenols, and it is also known as the inhibitor of steroid sulfotransferase enzyme.
💡
Conclusion & Impact:According to our literature knowledge, this is the first study to show the beneficial effects of DCNP on AB toxicity
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In Alzheimer's disease (AD), which is the most common cause of dementia, the accumulation of amyloid beta (AB) peptides has a causal role in the neurodegeneration process. AB peptides can induce synthesis of dehydroepiandrosterone (DHEA), which is a precursor of various steroids. Neurosteroids are modulators of neuronal survival and may have different effects depending on whether they are free or sulfa-conjugated. Nitrophenols can inhibit the aggregation of AB peptides at relatively low concentrations. 2,4dichloro-6-nitrophenol (DCNP) is a small water-soluble derivative of nitrophenols, and it is also known as the inhibitor of steroid sulfotransferase enzyme. However, the effects of DCNP on levels of distinct steroids and cell viability is not yet clearly known. This work aimed to investigate the effects of DCNP on various steroid levels and AB-induced cell death. SH-SY5Y cells were treated with DCNP (1 µM) and aggregates of AB 1-42 peptides (10 µM) for 72 hours. Cell viabilities were evaluated using MTT reduction and immune-fluorescence microscopy. The cellular changes of DHEA, DHEA sulfate, and sex steroids were determined using liquid chromatography-mass spectrometry (LC-MS/MS). The effect of DCNP on ultrastructure of AB aggregates was also examined with transmission electron microscopy. Seventy-two-hour treatment with DCNP significantly decreased DHEA sulfate and increased DHEA levels. Treatment with AB 1-42 aggregates decreased cell viability to approximately 50% and significantly changed DHEA and estradiol levels in SH-SY5Y cells. The ratio of cell death induced by AB 1-42 was reduced with DCNP treatment. When the AB aggregates were incubated in the aqueous solution with DCNP, the size of the aggregates became significantly smaller compared with the initial size. According to our literature knowledge, this is the first study to show the beneficial effects of DCNP on AB toxicity

Özet

Demansın en sık sebebi olan Alzheimer Hastalığı'nda Amiloid Beta (AB) birikimi nörodejeneratif süreçte nedensel rol oynar. AB peptid pek çok steroidin prekürsörü olan dehidroepiandrosteron (DHEA) sentezini indükler. Nörosteroidler nöronal canlılığı düzenler ve serbest ya da sülfa konjügat formda olmalarına göre farklı etkiler gösterirler. Nitrofenoller AB peptit agregasyonunu rölatif olarak düşük konsantrasyonlarda inhibe edebilirler. 2,4dikloro-6-nitrofenol (DCNP) nitrofenollerin küçük, suda çözünebilen türevi olup steroid sülfotransferaz enziminin inhibitörü olarak da bilinir. Ancak DCNP'nin farklı steroid düzeylerine ve hücre canlılığına etkileri henüz tam olarak bilinmemektedir. Bu çalışma DCNP'nin farklı steroid düzeylerine ve AB'nın indüklediği hücre ölümüne etkilerini araştırmayı hedeflemektedir. SH-SY5Y hücrelerine 72 saat süreyle DCNP (1µM) ve agrege edilmiş AB 1-42 peptit (10 µM) uygulandı. Hücre canlılığı MTT redüksiyon metodu ve immunfloresan mikroskop ile değerlendirildi. Hücresel DHEA, DHEA sülfat ve seks steroidlerinin değişimi LC-MS/MS ile belirlendi. DCNP'nin AB agregatlarının ultrastrüktürel yapısına olan etkisi transmisyon elektron mikroskop ile değerlendirildi. 72 saat boyunca DCNP uygulaması DHEA sülfat düzeyini anlamlı azaltırken, DHEA düzeyinde artışına neden oldu. SH-SY5Y hücrelerine AB 1-42 agregatlarının uygulanması, hücre canlılığını yaklaşık %50 azaltırken, DHEA ve östradiol düzeylerini de anlamlı değiştirmiştir. AB 1-42'nin indüklediği hücre ölüm oranı DCNP uygulaması ile azalmıştır. AB agregatları DCNP ile sulu ortamda inkübe edildiğinde agregat boyutlarında başlangıç ile kıyaslandığında anlamlı küçülme meydana gelmiştir. Bu çalışma, literatür bilgilerimize göre DCNP'nin AB toksisitesi üzerine faydalı etkilerinin gösterildiği ilk çalışma niteliğindedir

🔖

Cite This Article

ORMEN, M., CALAN, O. G., ERGUR, U. B., AKAN, P. (2022). Dikloronitrofenolün Amiloid Beta Toksisitesi ve Steroid Düzeylerine Etkisi. Journal of Neurological Sciences (Turkish), Cilt: 34 - Sayı: 1, 16–31. https://ajindex.com/articles/564839

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Tom SE, Hubbard RA, Crane PK et al. Characterization of dementia and Alzheimer's disease in an older population: updated incidence and life expectancy with and without dementia. Am J Public Health 2015;105:408-413
  2. Zhu X, Perry G, Smith MA, Wang X. Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2013;33:253-262
  3. Castellani RJ, Perry G. Pathogenesis and diseasemodifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res 2012;43:694-698
  4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356
  5. Morley JE, Farr SA. The role of amyloid-beta in the regulation of memory. Biochem Pharmacol 2014;88:479-485
  6. Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis. 2007;4:13-27
  7. Rafii MS. Update on Alzheimer's disease therapeutics. Rev Recent Clin Trials 2013;8:110- 118
  8. H. Amijee, D.I.C. Scopes. The quest for small molecules as amyloid inhibiting therapies for alzheimer’s disease. J Alzheimers Dis 2009; 17:33– 47
  9. Cole SL, Vassar R. The Alzheimer's disease betasecretase enzyme, BACE1. Mol Neurodegener 2007;2:22
  10. Evin G, Weidemann A. Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. Peptides 2002;23:1285-1297
  11. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 2010;120:185-193
  12. Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 2015;52:1- 18
  13. Schaeffer V, Meyer L, Patte-Mensah C, Eckert A, Mensah-Nyagan AG. Dose-dependent and sequence-sensitive effects of amyloid-beta peptide on neurosteroidogenesis in human neuroblastoma cells. Neurochem Int 2008;52:948-955
  14. Brown RC, Cascio C, Papadopoulos V. Pathways of neurosteroid biosynthesis in cell lines from human brain: regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid peptide. J Neurochem 2000;74:847-859
  15. Calan OG, Akan P, Cataler A, Dogan C, Kocturk S. Amyloid Beta Peptides Affect Pregnenolone and Pregnenolone Sulfate Levels in PC-12 and SHSY5Y Cells Depending on Cholesterol. Neurochem Res 2016;41:1700-1712
  16. Arevalo MA, Azcoitia I, Garcia-Segura LM. The neuroprotective actions of oestradiol and oestrog